PPD unit Evidera buys up real-world evidence company Medimix

PPD
Biopharma services company PPD bought Evidera back in 2016 and will beef up its offerings with its latest add-on buy. (PPD)

PPD is further boosting its real-world data offerings with its subsidiary Evidera snapping up Medimix.

The deal, financial details of which were not disclosed, comes three years after Evidera was bought out by PPD, which a year later in 2017 used the company to combine all of its medical affairs research operations (known as MARO) under the real-world research-focused subsidiary.

The addition of Medimix “enhances Evidera’s ability to leverage data to provide real-world evidence and insights for clients,” the company says in a statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Its new buy “scans, extracts and synthesizes big data and evidence-based information using a proprietary cloud-based visualization and analytics interface,” according to its blurb, with a focus on hematology and oncology.

RELATED: PPD combines medical affairs team with real-world research subsidiary Evidera

In essence, it uses a tech platform to scan across real-world usage (i.e., how patients/medical professionals are using drugs/medical devices) and relays this information back to clients to gain deeper insights across a much larger patient population.

Medimix does this via its LiveTracker, a cloud-based platform it says can “provide robust and comparable real-world evidence in more than 60 countries, including information on market structure, drug awareness and level of adoption, patient profiles, and treatment sequencing and outcomes.”

Evidera said it will leverage the platform and the data it generates to “power more efficient and effective real-world research that addresses burden of illness, resource utilization, safety, patient outcomes and other endpoints.”

“The addition of Medimix will expand our ability to help our clients plan for and generate the evidence needed to optimize the market access and commercial potential of their products,” said Karen Kaucic, M.D., president of Evidera. “We look forward to leveraging the capabilities and resources of Medimix to develop novel approaches to access and maximize the utility of real-world data.”

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Medidata is being bought by France’s Dassault Systemes in a deal designed to help the tech firm diversify deeper into the biopharma services world.

Synlogic has tapped Ginkgo Bioworks for a cell programming platform to support development of its pipeline of engineered microbes.